Apollomics (APLM)
Develops vebreltinib and other oncology candidates through global trials and territorial partnerships.
$27.35
At close+0.41 (+1.52%)
Something off on this page? Send us feedback.
Next report
Sep 24, 2026
in 21 days
EPS estimate
—
Revenue estimate
—
Fiscal quarter
Q1 FY26
EPSReportedEstimate
Jun '22Apr '23Sep '23Mar '24Dec '24Jun '25Mar '26Sep '26
Reported−$25.45−$273.51−$255.41−$24.39−$16.92−$11.37$3.80Pending
Estimate——−$0.16−$0.16————
Surprise——−159,533.5%−15,143.3%————
RevenueReportedEstimate
Jun '22Apr '23Sep '23Mar '24Dec '24Jun '25Mar '26Sep '26
Reported$595.0K−$272.0K$488.0K$333.0K−$1.6M$8.5M—Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2026 | — | — | — |
| Mar 2026 | — | $3.80 | — |
| Jun 2025 | — | −$11.37 | — |
| Apr 2025 | — | — | — |
| Dec 2024 | — | −$16.92 | — |
| Mar 2024 | −$0.16 | −$24.39 | −15,143.3% |
The latest year is open to everyone — the 8 quarters behind it read with an account. Sign in | |||
| Sep 2023 | |||
| Apr 2023 | |||
| Jun 2022 | |||
| Jun 2021 | |||
| Dec 2020 | |||
| Jun 2020 | |||
| Dec 2019 | |||
| Jun 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | — | — | — | — | — | — | — |
| Mar 30, 2026 | — | $3.80 | — | — | — | — | −5.1% |
| Jun 30, 2025 | — | −$11.37 | — | — | $8.5M | — | −2.4% |
| Apr 3, 2025 | — | — | — | — | — | — | — |
| Dec 31, 2024 | — | −$16.92 | — | — | −$1.6M | — | +10.8% |
| Mar 28, 2024 | −$0.16 | −$24.39 | −15,143.3% | — | $333.0K | — | −2.7% |
The latest year is open to everyone — the 8 quarters behind it read with an account. Sign in | |||||||
| Sep 28, 2023 | |||||||
| Apr 28, 2023 | |||||||
| Jun 30, 2022 | |||||||
| Jun 30, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Jun 30, 2019 | |||||||